FamiCord (V3V) Status Update summary

Market position and operations

• Holds the leading position in Europe with about 55% market share and is third globally in stem cell banking.

• Operates in over 30 companies across Europe, with 13 processing labs and additional storage facilities.

• Present in 75% of Europe by access to newborns, with dominant market shares in Germany and Poland.

• Uses a network of partners in regions like the Balkans and has ambitions to become number one in the UK and Emirates.

• Expanded into the Gulf region with a new lab in Dubai and maintains a small office in Hong Kong.

Industry trends and challenges

• European stem cell banking market is consolidating, shrinking from 150 to about 55-60 players over 15 years.

• Regulatory diversity and local laws create high entry barriers and require tailored strategies for each country.

• Market faces challenges from declining birth rates, but low penetration (2% average) leaves significant growth potential.

• Industry trust was impacted by a major competitor's bankruptcy and COVID-19 disruptions.

• Geopolitical events like the Ukraine war have had limited but lingering effects, especially in Germany.

Product and service development

• Offers stem cell and tissue banking, including cord blood, placenta, and amnion, with new services like placenta banking rolled out since 2021.

• Placenta banking is gaining traction, with 25-30% of clients opting for it; regulatory approval in Germany is pending, while Portugal launch is set for Q4 2024.

• Provides B2B CDMO services, supplying cells and advanced medicinal products for clinical trials.

• Focuses on increasing client lifetime value and reducing acquisition costs through operational excellence and new product offerings.